Business Context and Reporting Period
This Form 6-K filing by Lichen China Limited (also referred to as Lichen International Ltd) covers the month of January 2025, with a report date of January 3, 2025. The filing details two registered direct offerings of Class A ordinary shares and pre-funded warrants conducted in late December 2024 to raise capital for working capital and general corporate purposes.
Key Financial Metrics and Capital Raise
- December 26 Offering: Gross proceeds of approximately $2.8 million from the sale of 10,433,333 shares at $0.14 per share and 9,566,667 pre-funded warrants at $0.139 per warrant.
- December 29 Offering: Gross proceeds of approximately $3.1 million from the sale of 13,200,000 shares at $0.125 per share and 11,800,000 pre-funded warrants at $0.124 per warrant.
- Total Gross Proceeds: Approximately $5.9 million combined from both closings.
- Transaction Costs: Placement agent fees of 7.0% of gross proceeds for each offering, plus reimbursement of legal and other expenses up to $50,000 per offering.
- Share Issuance: All pre-funded warrants were exercised in full as of the report date, resulting in the issuance of an additional 21,366,667 Class A Ordinary Shares.
- Operating Metrics: The filing does not provide revenue, profit, cash flow, margins, or debt figures.
Material Changes and Offering Structure
The company executed two separate closings within a three-day period. The December 29 offering price ($0.125) was lower than the December 26 offering price ($0.14), indicating a downward price adjustment between transactions. The use of pre-funded warrants in both transactions was necessitated by beneficial ownership limitations, preventing purchasers from exceeding 9.99% ownership of the outstanding share capital. All warrants were immediately exercisable at $0.001 per share and were fully exercised by the date of this report.
Guidance, Restrictions, and Risks
- Use of Proceeds: Net proceeds are designated for working capital and general corporate purposes.
- Lock-Up Agreements: Directors and executive officers are restricted from selling or transferring company securities for 90 days following each closing.
- Issuance Restrictions: The company agreed not to issue or announce the issuance of Class A Ordinary Shares or equivalent securities for 60 days following each closing. Additionally, the company is barred from conducting variable rate transactions for 90 days following each closing.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from expectations due to inherent uncertainties and risks described in the company's Form 20-F.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 7% placement fees and up to $50,000 in expense reimbursements for each offering.
- Confirm the total number of outstanding shares post-exercise of all pre-funded warrants to assess dilution impact.
- Review the company's most recent Form 20-F for current liquidity status, as this filing does not provide balance sheet data.
- Monitor compliance with the 60-day and 90-day issuance and lock-up restrictions to prevent unexpected dilution or insider selling.
- Assess the company's ability to deploy the $5.9 million in gross proceeds effectively given the lack of specific operational guidance in this filing.